Bezafibrate is a lipid - regulating drug. It belongs to the fibrate class of lipid - lowering medications. It can reduce cholesterol levels. It inhibits 3 - hydroxy - 3 - methylglutaryl - coenzyme A (HMG - CoA) reductase, the rate - limiting enzyme in cholesterol synthesis, thereby reducing cholesterol synthesis. It also increases the decomposition and metabolism of low - density lipoproteins, which in turn lowers cholesterol levels. Additionally, it can decrease triglyceride levels. By inhibiting acetyl - CoA reductase, it reduces triglyceride synthesis. It activates lipoprotein lipase in the liver, increasing the elimination of triglycerides and thus reducing triglyceride levels.

This drug can serve as a first - line lipid - lowering agent and is suitable for hyperlipidemia caused by various reasons, especially for patients with hyperlipidemia complicated by diabetes.